Tested Applications
| Positive WB detected in | MJ cells |
| Positive FC detected in | PHA treated human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Flow Cytometry (FC) | FC : 0.20 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
20006-1-AP targets CD134/OX40 in WB, FC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | tumor necrosis factor receptor superfamily, member 4 |
| Calculated Molecular Weight | 29 kDa |
| Observed Molecular Weight | 50-55 kDa, 40 kDa |
| GenBank Accession Number | NM_003327 |
| Gene Symbol | CD134 |
| Gene ID (NCBI) | 7293 |
| RRID | AB_10733472 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P43489 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CD134 (OX40) is a member of the TNFR-superfamily of receptors. Predominantly expressed on activated T cells, CD134 is activated by its cognate ligand CD134L (OX40L) and functions as a T cell co-stimulatory molecule. CD134-CD134L interactions have been proposed as a potential therapeutic target for treating autoimmunity (PMID: 26215166). CD134 can interact with TRAF2, TRAF3, and TRAF5.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CD134/OX40 antibody 20006-1-AP | Download protocol |
| WB protocol for CD134/OX40 antibody 20006-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The CD134/OX40 Polyclonal antibody (Cat# 20006-1-AP) has 4 citations published in NPJ Precision Oncology, Frontiers in Immunology (2 papers), and Disease Markers. The associated research fields include oncology (multiple myeloma, oral squamous cell carcinoma, hepatocellular carcinoma) and immunology (immune-related gene signatures, costimulatory molecule profiling, and anti-OX40 monoclonal antibody development for cancer therapy).
| Species | Application | Title |
|---|---|---|
NPJ Precis Oncol Y chromosome-linked EIF1AY deletion drives sex differences in multiple myeloma.
| ||
Front Immunol Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy. | ||
Front Immunol A Novel Immune-Related Gene Signature to Identify the Tumor Microenvironment and Prognose Disease Among Patients With Oral Squamous Cell Carcinoma Patients Using ssGSEA: A Bioinformatics and Biological Validation Study | ||
Dis Markers Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma |
